195 related articles for article (PubMed ID: 36183976)
1. NSUN2-mediated mRNA m
Song D; An K; Zhai W; Feng L; Xu Y; Sun R; Wang Y; Yang YG; Kan Q; Tian X
Genomics Proteomics Bioinformatics; 2023 Aug; 21(4):823-833. PubMed ID: 36183976
[TBL] [Abstract][Full Text] [Related]
2. NSUN2 promotes lung adenocarcinoma progression through stabilizing PIK3R2 mRNA in an m
Du X; Cheng C; Yang Y; Fan B; Wang P; Xia H; Ni X; Liu Q; Lu L; Wei L
Mol Carcinog; 2024 May; 63(5):962-976. PubMed ID: 38411298
[TBL] [Abstract][Full Text] [Related]
3. NSUN2-mediated RNA 5-methylcytosine promotes esophageal squamous cell carcinoma progression via LIN28B-dependent GRB2 mRNA stabilization.
Su J; Wu G; Ye Y; Zhang J; Zeng L; Huang X; Zheng Y; Bai R; Zhuang L; Li M; Pan L; Deng J; Li R; Deng S; Zhang S; Zuo Z; Liu Z; Lin J; Lin D; Zheng J
Oncogene; 2021 Sep; 40(39):5814-5828. PubMed ID: 34345012
[TBL] [Abstract][Full Text] [Related]
4. Aberrant NSUN2-mediated m
Sun Z; Xue S; Zhang M; Xu H; Hu X; Chen S; Liu Y; Guo M; Cui H
Oncogene; 2020 Nov; 39(45):6906-6919. PubMed ID: 32978516
[TBL] [Abstract][Full Text] [Related]
5. NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m
Zhang X; An K; Ge X; Sun Y; Wei J; Ren W; Wang H; Wang Y; Du Y; He L; Li O; Zhou S; Shi Y; Ren T; Yang YG; Kan Q; Tian X
Breast Cancer Res; 2024 Jun; 26(1):94. PubMed ID: 38844963
[TBL] [Abstract][Full Text] [Related]
6. RNA bisulfite sequencing reveals NSUN2-mediated suppression of epithelial differentiation in pancreatic cancer.
Chen SY; Chen KL; Ding LY; Yu CH; Wu HY; Chou YY; Chang CJ; Chang CH; Wu YN; Wu SR; Hou YC; Lee CT; Chen PC; Shan YS; Huang PH
Oncogene; 2022 May; 41(22):3162-3176. PubMed ID: 35501460
[TBL] [Abstract][Full Text] [Related]
7. NSUN2 promotes osteosarcoma progression by enhancing the stability of FABP5 mRNA via m
Yang M; Wei R; Zhang S; Hu S; Liang X; Yang Z; Zhang C; Zhang Y; Cai L; Xie Y
Cell Death Dis; 2023 Feb; 14(2):125. PubMed ID: 36792587
[TBL] [Abstract][Full Text] [Related]
8. RNA m
Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
[TBL] [Abstract][Full Text] [Related]
9. Circular RNA ITCH increases sorafenib-sensitivity in hepatocellular carcinoma via sequestering miR-20b-5p and modulating the downstream PTEN-PI3K/Akt pathway.
Li X; Yin X; Bao H; Liu C
Mol Cell Probes; 2023 Feb; 67():101877. PubMed ID: 36442661
[TBL] [Abstract][Full Text] [Related]
10. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
11. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
12. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways.
Cai W; Ma Y; Song L; Cao N; Gao J; Zhou S; Tang X
BMC Cancer; 2023 Jan; 23(1):87. PubMed ID: 36698167
[TBL] [Abstract][Full Text] [Related]
13. NSUN2-mediated m
Zuo S; Li L; Wen X; Gu X; Zhuang A; Li R; Ye F; Ge S; Fan X; Fan J; Chai P; Lu L
Clin Transl Med; 2023 May; 13(5):e1273. PubMed ID: 37228185
[TBL] [Abstract][Full Text] [Related]
14. NSUN2-Mediated m
Lu J; Zhang M; Liu Z; Guo L; Huang P; Xia W; Li J; Lv J; Cheung HH; Ding C; Li H; Huang B
Lab Invest; 2024 Apr; 104(4):100327. PubMed ID: 38237738
[TBL] [Abstract][Full Text] [Related]
15. Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.
Zhu W; Wan F; Xu W; Liu Z; Wang J; Zhang H; Huang S; Ye D
Clin Transl Med; 2022 Sep; 12(9):e1028. PubMed ID: 36169095
[TBL] [Abstract][Full Text] [Related]
16. Y-box binding protein 1 augments sorafenib resistance
Liu T; Xie XL; Zhou X; Chen SX; Wang YJ; Shi LP; Chen SJ; Wang YJ; Wang SL; Zhang JN; Dou SY; Jiang XY; Cui RL; Jiang HQ
World J Gastroenterol; 2021 Jul; 27(28):4667-4686. PubMed ID: 34366628
[TBL] [Abstract][Full Text] [Related]
17. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
[TBL] [Abstract][Full Text] [Related]
18. NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation.
Hu Y; Chen C; Tong X; Chen S; Hu X; Pan B; Sun X; Chen Z; Shi X; Hu Y; Shen X; Xue X; Lu M
Cell Death Dis; 2021 Sep; 12(9):842. PubMed ID: 34504059
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
20. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.
Liu J; Zhang C; Lin M; Zhu W; Liang Y; Hong X; Zhao Y; Young KH; Hu W; Feng Z
Oncotarget; 2014 May; 5(9):2635-47. PubMed ID: 24797434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
